-
1.发明公开公开(公告)号：US20230277471A1
公开(公告)日：2023-09-07
申请号：US18126251
申请日：2023-03-24
IPC分类号： A61K9/51 , A61K9/127 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/395 , A61K45/06
CPC分类号： A61K9/51 , A61K9/127 , A61K9/1275 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/3955 , A61K45/06
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
公开(公告)号：US11052052B2
公开(公告)日：2021-07-06
申请号：US16527579
申请日：2019-07-31
IPC分类号： A61K9/51 , A61K9/127 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/395 , A61K45/06
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
公开(公告)号：US10369114B2
公开(公告)日：2019-08-06
申请号：US15603992
申请日：2017-05-24
IPC分类号： A61K9/51 , A61K31/7034 , A61K31/713 , A61K31/12 , A61K31/137 , A61K31/19 , A61K38/14 , A61K38/28 , A61K45/06 , A61K39/29 , A61K39/395 , A61K31/546 , A61K9/127
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
4.发明授权公开(公告)号：US12005146B2
公开(公告)日：2024-06-11
申请号：US18126251
申请日：2023-03-24
IPC分类号： A61K9/51 , A61K9/127 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/395 , A61K45/06
CPC分类号： A61K9/51 , A61K9/127 , A61K9/1275 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/3955 , A61K45/06
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
5.发明授权公开(公告)号：US11633364B2
公开(公告)日：2023-04-25
申请号：US17337283
申请日：2021-06-02
IPC分类号： A61K9/51 , A61K9/127 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/395 , A61K45/06
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
公开(公告)号：US20200069598A1
公开(公告)日：2020-03-05
申请号：US16527579
申请日：2019-07-31
IPC分类号： A61K9/51 , A61K9/127 , A61K31/12 , A61K31/137 , A61K31/19 , A61K31/546 , A61K31/7034 , A61K31/713 , A61K38/14 , A61K38/28 , A61K39/29 , A61K39/395 , A61K45/06
摘要： The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.017 秒)
